Evidence map›Paper›PMID 29890363›Full record

ArticleBiomaterials2018

Development and MPI tracking of novel hypoxia-targeted theranostic exosomes.

Kyung Oh Jung, Hunho Jo, Jung Ho Yu, Sanjiv Sam Gambhir, Guillem Pratx

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kyung Oh JungDepartment of Radiation Oncology, Division of Medical Physics, Stanford University School of Medicine, Stanford University, Stanford, CA, USA; Molecular Imaging Program at Stanford (MIPS), School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: blpg86@stanford.edu.
Hunho JoDepartment of Radiology, School of Medicine, Stanford University, Stanford, CA, USA.
Jung Ho YuDepartment of Radiology, School of Medicine, Stanford University, Stanford, CA, USA; Molecular Imaging Program at Stanford (MIPS), School of Medicine, Stanford University, Stanford, CA, USA.
Sanjiv Sam GambhirDepartment of Radiology, School of Medicine, Stanford University, Stanford, CA, USA; Molecular Imaging Program at Stanford (MIPS), School of Medicine, Stanford University, Stanford, CA, USA.
Guillem PratxDepartment of Radiation Oncology, Division of Medical Physics, Stanford University School of Medicine, Stanford University, Stanford, CA, USA; Molecular Imaging Program at Stanford (MIPS), School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: pratx@stanford.edu.

Funding

Quantitative Imaging of Cancer Drug Resistance via Radioluminescence MicroarraysR01CA186275 · NCI · STANFORD UNIVERSITY · PI PRATX, GUILLEM · 2014 to 2018
$1.7M
NCI NIH HHS R01 CA186275
6 · The paper itself

Abstract

Treating the hypoxic region of the tumor remains a significant challenge. The goals of this study are to develop an exosome platform that can target regions of tumor hypoxia and that can be monitored in vivo using magnetic particle imaging (MPI). Four types of exosomes (generated under hypoxic or normoxic conditions, and with or without exposure to X-ray radiation) were isolated from MDA-MB-231 human breast cancer cells. Exosomes were labeled by DiO, a fluorescent lipophilic tracer, to quantify their uptake by hypoxic cancer cells. Subsequently, the exosomes were modified to carry SPIO (superparamagnetic iron oxide) nanoparticles and Olaparib (PARP inhibitor). FACS and fluorescence microscopy showed that hypoxic cells preferentially take up exosomes released by hypoxic cells, compared with other exosome formulations. In addition, the distribution of SPIO-labeled exosomes was successively imaged in vivo using MPI. Finally, the therapeutic efficacy of Olaparib-loaded exosomes was demonstrated by increased apoptosis and slower tumor growth in vivo. Our novel theranostic platform could be used as an effective strategy to monitor exosomes in vivo and deliver therapeutics to hypoxic tumors.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBreast NeoplasmsCell Line, TumorDrug CarriersDrug Delivery SystemsExosomesFemaleFlow CytometryFluorescent DyesHumansMagneticsMagnetite NanoparticlesMice, NudeMicroscopy, FluorescenceAntineoplastic AgentsDrug CarriersFluorescent DyesMagnetite NanoparticlesolaparibPhthalazinesPiperazinesCancerDrug deliveryExosomesHypoxiaMagnetic particle imaging (MPI)

Identifiers

PMID29890363
PMCPMC6019194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.